Skip to main content

Table 3 Subgroup analysis of medical expenditures for esophageal cancer diagnosis and treatment per patient

From: Medical expenditure for esophageal cancer in China: a 10-year multicenter retrospective survey (2002–2011)

Variable

Expenditure per patient during 2002–2011 (CNY)

Statisticsa

P

Expenditure per patient during 2009–2011 (CNY)

Statisticsa

P

Overall

38,666 (38,178–39,155)

  

45,319 (44,425–46,213)

  

Region

 

649.44

<0.001

 

306.1

<0.001

 Eastern

41,943 (41,202–42,684)

  

47,213 (46,021–48,406)

  

 Central

40,410 (39,646–41,173)

  

52,765 (51,100–54,430)

  

 Western

30,234 (29,200–31,269)

  

32,555 (30,585–34,526)

  

Hospital type

−6.75

<0.001

 

−1.20

0.228

 General hospital

36,684 (35,663–37,704)

  

45,706 (43,883–47,529)

  

 Specialized hospital

39,256 (38,700–39,812)

  

45,182 (44,157–46,207)

  

Hospital level

25.60

<0.001

 

13.26

<0.001

 3A

40,134 (39,625–40,643)

  

46,751 (45,824–47,677)

  

 3A less

22,052 (20,621–23,483)

  

26,409 (23,612–29,206)

  

Number of clinical visits per patient

889.53

<0.001

 

204.28

< 0.001

 1

29,089 (28,651–29,528)

  

34,858 (33,981–35,735)

  

 2

46,633 (45,530–47,737)

  

53,959 (52,002–55,917)

  

 3

59,441 (57,524–61,357)

  

60,407 (57,497–63,317)

  

 4+

68,928 (66,774–71,082)

  

69,055 (65,749–72,360)

  

Gender

5.64

<0.001

 

1.84

0.066

 Male

39,521 (38,961–40,082)

  

46,046 (45,017–47,074)

  

 Female

35,585 (34,605–36,564)

  

42,768 (40,976–44,561)

  

Age at diagnosis (years)

8.65

<0.001

 

14.42

<0.001

 <45

37,796 (35,539–40,054)

  

49,384 (43,380–55,388)

  

 45–54

39,237 (38,172–40,302)

  

50,732 (48,367–53,096)

  

 55–64

39,588 (38,792–40,384)

  

46,572 (45,139–48,006)

  

 ≥65

37,452 (36,647–38,257)

  

41,741 (40,426–43,057)

  

Pathologic type

23.95

<0.001

 

11.61

<0.001

 Squamous cell carcinoma

40,711 (40,173–41,250)

  

48,242 (47,233–49,250)

  

 Others

30,216 (29,032–31,399)

  

35,576 (33,636–37,516)

  

Clinical stage

55.51

<0.001

 

21.80

<0.001

 I

34,460 (32,902–36,017)

  

40,000 (36,878–43,122)

  

 II

39,302 (38,526–40,079)

  

47,978 (46,381–49,575)

  

 III

40,353 (39,491–41,214)

  

44,962 (43,616–46,309)

  

 IV

37,432 (36,180–38,685)

  

42,972 (40,749–45,194)

  

Type of therapy

 

758.66

<0.001

 

270.53

<0.001

 Surgery

38,492 (37,890–39,094)

  

47,778 (46,548–49,008)

  

 Surgery and chemotherapy

51,503 (50,316–52,691)

  

63,843 (61,535–66,151)

  

 Radiotherapy

27,933 (26,787–29,079)

  

29,085 (27,471–30,699)

  

 Chemotherapy

27,805 (26,310–29,299)

  

35,671 (33,121–38,222)

  

 Radiotherapy and chemotherapy

53,907 (51,867–55,946)

  

57,234 (53,865–60,603)

  

 Surgery and radiotherapy

57,725 (55,041–60,409)

  

62,438 (58,708–66,167)

  

 Palliative care

13,846 (12,626–15,067)

  

15,627 (13,187–18,067)

  

 Others

23,057 (20,564–25,550)

  

21,821 (18,386–25,256)

  
  1. All expenditure data are presented as mean with 95% confidence interval in parentheses
  2. CNY Chinese Yuan
  3. aThe two-sample Student t test after logarithm transition was used for binary classification variables, including hospital type, hospital level, gender, and pathologic type. The ANOVA test after logarithm transition was used for other multiple categorical variables, including region, number of clinical visits per patient, age at diagnosis, and clinical stage
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us